Full-Time

Clinical and Economic Research Patient Classification Senior Research Specialist

Posted on 11/23/2025

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$183.3k - $224k/yr

+ Variable Incentive Pay

No H1B Sponsorship

Maryland, USA

Remote

On-site onboarding travel to a designated company location during initial days; travel expenses covered.

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor's Degree or higher from an accredited university and seven years in a business healthcare related field, healthcare policy, health policy, health research, health economics, clinical informatics in a private, public, government or military environment
  • OR High School Diploma/GED AND fourteen years of in healthcare related field, healthcare policy, health policy, health research, health economics, clinical informatics in a private, public, government or military environment
  • AND four years healthcare organization experience (e.g. government payer, provider, hospital, insurance company, health care consulting, software, research, services firm)
  • Must be legally authorized to work in country of employment without sponsorship for employment visa status (e.g., H1B status)
  • Work location is Remote-United States
  • Travel: May include up to 10% (domestic/international)
  • Onboarding requirement for new hires with start date October 1, 2025 or later, travel to designated company location for on-site onboarding during initial days of employment (travel arrangements paid by company)
Responsibilities
  • Contribute subject matter expertise in the research, clinical logic content design, evaluation, development and application of Solventum Clinical and Economic Research clinical categorical patient classification methodologies for inpatient, outpatient facility, population care, risk adjustment and payment with particular focus on Solventum’s outpatient Enhanced Ambulatory Patient Groups (EAPGs), inpatient All Patient Refined DRGs (APR-DRGs), and Clinical Risk Groups (CRGs) to advance effective and efficient payment and utilization solutions and ensuring its meaningful integration into end user operations.
  • Collaborate with research team to create and develop research approaches and plans with academic rigor that combine the power of categorical models with big data to drive further refinement of our models enhancing our analytic abilities to express and summarize clinically relevant results of analyzing big data making results that much more understandable and actionable across the entire health system.
  • Advance and enhance methodology impact and usability in improving payment accuracy and measure efficiency by users across payer, provider, government, business partner, and non-profit clients.
  • Bring an apply strong and broad understanding of the applicable healthcare landscape and inpatient/outpatient/population payment classification solutions / risk adjustment. Bring forward emerging clinical categorical patient classification models and trends in the healthcare delivery market and usage in US Medicare, Medicaid, commercial and global health care policy. Perform and interpret review of healthcare patient classification, healthcare delivery reform and market trends related to EAPG, APR-DRG and CRGs.
  • Support application of clinical categorical patient classification systems into quality and patient safety methodologies and approaches/risk adjustment.
  • Publish articles, blogs and comments on patient classification systems related issues as well as rebuttals to articles on patient classification systems
  • Guide Product Owner and marketing/sales team in understanding and communicating the value of the methodologies and enhancements to drive growth. Support Product Owner in efforts to influence the adoption of patient classification systems with payers, business partners both domestically and internationally.
Desired Qualifications
  • The candidate should have a strong familiarity with Solventum’s patient classification systems including APR-DRGs, CRGs and EAPGs.
  • PhD or MD or equivalent degree completed
  • Strong knowledge of payment policy both within the US and Internationally.
  • Experience of working with and/or within health systems, health plans, State Medicaid programs, Commercial payers, value-based care arrangements, Medicaid MCOs or international.
  • Strong knowledge of disease and procedure classification systems ICD-10-CM/PCS diagnosis and procedure coding, CPT/HCPCS.
  • Advanced knowledge of medical terminology, anatomy, physiology, disease processes, surgical and non-surgical procedures, medical literature and revenue-based regulatory requirements
  • Strong analytical thinking, strategic thinker, pattern recognition, creative methodical, detail oriented with clear written and verbal communication skills required to effectively communicate complex topics and information in a way that experts and non-experts will understand
  • A demonstrated ability to take initiative and responsibility for assignments is a must. Working style is able to prioritize, multi-task, focus on goals, takes accountability and manages time well
  • Must be comfortable in a fast-paced environment with challenging deadlines, and multiple patient classification projects. Ability to excel in a complex, cross-functional and dynamic team work environment and strong business acumen with high integrity and work ethic.
  • Candidate must have prior experience presenting health care related topics at national or regional conferences as well as have been lead author on healthcare related peer reviewed journal articles demonstrating evidence of thought leadership.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • $200M Eagan Innovation Hub accelerates wound care and digital health R&D.
  • Acera Surgical acquisition expands into $900M synthetic tissue matrices market.
  • $500M cost-savings program and $1B buyback boost 2026 EPS to $6.60.

What critics are saying

  • Q1 2026 revenue drops 4.9% as MedSurg demand declines post-divestiture.
  • ERP failures and 3M service agreements delay savings through 2026.
  • 3M's $648M share sale in early 2026 depresses SOLV stock price.

What makes Solventum unique

  • Solventum leads advanced wound care with market-dominant products post-3M spin-off.
  • Filtek brand holds dominant share in $2B dental composite market since 2025.
  • Health IT software serves 75% of U.S. hospitals with AI-assisted coding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Simply Wall St
Apr 5th, 2026
Solventum opens $200M Innovation Hub as CAO prepares to retire

Solventum Corporation has opened a $200 million Innovation Hub in Eagan, Minnesota, housing over 1,800 employees and supported by approximately $13 million in state business development funding. The facility focuses on research and development in healthcare innovation, particularly advanced wound care, sterilisation and digital health. The opening coincides with Chief Accounting Officer Mary Wilcox announcing her retirement, effective once a successor is appointed. Wilcox informed the company of her intention on 20 March 2026. The Innovation Hub supports Solventum's emphasis on new product development following its separation from 3M. However, analysts note that near-term execution risks around ERP implementation and supply chain transition remain key factors for investors to monitor.

Yahoo Finance
Mar 1st, 2026
Solventum sells Purification unit, buys Acera Surgical, launches $1B buyback in first year post-3M spin

Solventum reported fourth-quarter sales of $2.0 billion, with organic growth of 3.5% year-over-year, though reported revenue declined 3.7% due to its Purification & Filtration divestiture and the Acera acquisition. Non-GAAP earnings per share reached $1.57, whilst adjusted operating margin was 19.9%. Gross margin fell 230 basis points to 53.5%, with roughly 150 basis points attributed to one-time separation costs from 3M. For 2026, the company guided organic sales growth of 2%–3%, operating margin of 21%–21.5%, and EPS of $6.40–$6.60. Management expects free cash flow around $200 million, or roughly $1 billion excluding separation and divestiture costs. The company closed its acquisition of Acera Surgical to enter the synthetic tissue market and launched a $1 billion share buyback programme. Solventum aims to exit approximately 90% of transitional service agreements with 3M by year-end 2026.

Yahoo Finance
Feb 26th, 2026
Solventum beats quarterly estimates as surgical product demand drives $2B revenue

Solventum, a Minnesota-based medical device maker, beat Wall Street estimates for the fourth quarter, driven by strong demand for wound care and sterilisation products. Revenue reached $2 billion, surpassing analysts' expectations of $1.96 billion, whilst adjusted earnings per share came in at $1.57 versus estimates of $1.50. The company's MedSurg business, which accounts for over half of total revenue, saw sales rise 5.2% year-on-year to $1.24 billion. Solventum forecast 2026 adjusted profit of $6.40 to $6.60 per share, above Wall Street expectations of $6.34. The company is acquiring Acera Surgical for up to $850 million to expand its wound care portfolio and has launched a four-year programme expected to deliver $500 million in annual savings.

Yahoo Finance
Feb 26th, 2026
Solventum Q4 earnings beat expectations with $2B revenue, projects $6.40-$6.60 per share for 2025

Solventum reported fourth-quarter net income of $63 million, or $1.57 per share on an adjusted basis, exceeding Wall Street expectations of $1.50 per share. The Maplewood, Minnesota-based healthcare company posted revenue of $2 billion, surpassing analyst forecasts of $1.97 billion. For the full year, Solventum reported profit of $1.56 billion, or $8.88 per share, with revenue of $8.32 billion. The company expects full-year earnings between $6.40 and $6.60 per share.

PR Newswire
Feb 26th, 2026
Solventum reports Q4 2025 results with 3.5% organic sales growth, sets 2026 guidance

Solventum reported fourth quarter 2025 results with sales of $2 billion, down 3.7% on a reported basis but up 3.5% organically. GAAP diluted earnings per share were $0.36, whilst adjusted diluted earnings per share reached $1.57. Operating cash flow totalled $96 million, with free cash flow of $33 million. The healthcare company's organic sales growth was driven by its Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions. Full-year 2025 results exceeded expectations for both sales and earnings per share. For 2026, Solventum projects organic sales growth of 2.0% to 3.0%, adjusted earnings per share of $6.40 to $6.60, and free cash flow of approximately $200 million. The company, which spun off from 3M, continues its transformation journey.

INACTIVE